Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2

79MO - PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Date

27 Mar 2021

Session

Mini Oral session 2

Presenters

Fiona McDonald

Citation

Journal of Thoracic Oncology (2021) 16 (suppl_4): S737-S747.

Authors

F. McDonald1, F. Mornex2, M.C. Garassino3, A.R. Filippi4, D. Christoph5, V.D. Haakensen6, A. Agbarya7, M. Van den Heuvel8, P. Vercauter9, C. Chouaid10, E. Pichon11, S. Siva12, L. Steinbusch8, I. Peretz13, B. Solomon14, L. Decoster15, W. Sawyer16, A. Allen17, M. Licour18, N. Girard19

Author affiliations

  • 1 Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 2 Centre Hospitalier Universitaire de Lyon, Lyon/FR
  • 3 Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Chicago/US
  • 4 Radiation Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia PV/IT
  • 5 Evangelische Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen/DE
  • 6 Oslo University Hospital, Oslo/NO
  • 7 Bney Zion Medical Center, Haifa/IL
  • 8 The Netherlands Cancer Institute, Amsterdam/NL
  • 9 Onze-Lieve-Vrouw Ziekenhuis Aalst, Aalst/BE
  • 10 CH Intercommunal de Créteil, Créteil/FR
  • 11 CHRU de Tours, Hôpital Bretonneau, Tours/FR
  • 12 Sir Peter MacCallum Cancer Centre, Melbourne/AU
  • 13 Clalit Health Services, Tel Aviv/IL
  • 14 Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne/AU
  • 15 Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels/BE
  • 16 AstraZeneca, Cambridge/GB
  • 17 AstraZeneca, Gaithersburg/US
  • 18 Astrazeneca, Paris/FR
  • 19 Institut Curie, 75005 - Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 79MO

Background

The PACIFIC regimen (up to 12 months of durvalumab treatment in pts with unresectable stage III non-small cell lung cancer [NSCLC] who did not progress after platinum-based concurrent chemoradiotherapy [cCRT]) is now standard of care. Insights into durvalumab use outside the clinical trial setting are needed.

Methods

PACIFIC-R (NCT03798535) is a large international, observational study of pts with unresectable Stage III NSCLC who received ≥1 dose of durvalumab (10 mg/kg Q2W) as part of an AstraZeneca-initiated expanded access programme (September 2017–December 2018). Pts must have completed platinum-based chemotherapy (CT) concurrent or sequential to radiotherapy (RT) within the previous 12 weeks without evidence of disease progression. Data will be retrospectively collected up to 5 years after enrolment.

Results

The full analysis set (N = 1155) showed no significant differences in baseline demographics and disease characteristics by PD-L1 expression status (tested pts: ≥1% [n = 574] vs <1% [n = 138]). A majority of pts had received cCRT (n = 893). Pts who had received sequential CRT (sCRT; n = 163) were generally older (37.4% vs 28.4% aged ≥70 years); a higher proportion had larger tumour volume (25.0% vs 15.9% >70 mm). Median total RT dose (overall: 65 Gy) and duration (overall: 1.5 months) reflected local practice. For platinum-based CT regimens, vinorelbine was favoured in France/Germany/UK; paclitaxel in Australia/Israel; and etoposide in Netherlands/Belgium/Norway. Median CT duration ranged from 0.8 to 2.3 months (overall: 1.6 months). Median time of durvalumab start from end of CRT varied from 39 to 89 days (overall: 52 days). Most commonly reported adverse events of special interest (AESIs) in the first 3 months of durvalumab treatment were pneumonitis (10.6%) and endocrinopathies (6.8%), leading to permanent treatment discontinuation in 4.8% and 0.2% of pts, respectively.

Conclusions

Real-world characteristics of PACIFIC-R pts reflect the PACIFIC population (only cCRT was allowed per protocol in PACIFIC). Time to durvalumab start from end of CRT was longer than in PACIFIC (except France: durvalumab start ≤6 weeks from end of CRT per protocol). Permanent discontinuation due to AESIs was infrequent.

Clinical trial identification

NCT03798535.

Editorial acknowledgement

Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Carole Mongin-Bulewski of Cirrus Communications (Macclesfield, UK), an Ashfield company, and was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca plc.

Funding

AstraZeneca.

Disclosure

F. McDonald: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self): Elekta; Advisory/Consultancy: Accuracy; Research grant/Funding (institution): MSD. M.C. Garassino: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), PI, MISP in Thimic malignancies; Speaker, advisory board: Eli Lilly; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Local PI, Enrollment in clinical Trials in NSCLC; Speaker; advisory board: Otsuka Pharma; Advisory/Consultancy, Research grant/Funding (self), PI, Enrollment and Steering Committee in clinical Trials in NSCLC;consulting, advisory boards, lectures;steering committee: AstraZeneca; Advisory/Consultancy, Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC; advisory board: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC; Speaker, advisory board: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC; Speaker, advisory board: Roche; Advisory/Consultancy, Research grant/Funding (self), PI, MISP MISP Sunitinib in thymic malignancies; advisory board: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC; Speaker, advisory board: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Institutional Grants; Advisory board; Speaker: Incyte; Advisory/Consultancy: Inivata; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Research grant/Funding (self), PI, Enrollment in clinical Trials Thimic malignancies: Tiziana Sciences; Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC: Clovis; Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC: Merck Serono; Advisory/Consultancy, Research grant/Funding (self), PI, Enrollment in clinical Trials in Mesothelioma; advisory board: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), PI, Enrollment in clinical Trials in NSCLC; consulting, advisory boards, lectures; steering committee: MSD; Advisory/Consultancy, Research grant/Funding (self), Local PI, Enrollment and Steering committee in clinical Trials in NSCLC; advisory board: GlaxoSmithKline S.p.A.; Advisory/Consultancy, Research grant/Funding (self), Advisory board; PI, Enrollment in clinical Trials: Sanofi-Aventis; Advisory/Consultancy, Research grant/Funding (self), PI, Enrollment in clinical Trials; Advisory board; steering committee: Spectrum Pharmaceutcials; Advisory/Consultancy, Research grant/Funding (self), PI, Enrollment in clinical Trials; Advisory board; steering committee: Blueprint Medicine; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Daiichi Sankyo; Research grant/Funding (institution): Merck KGaA; Advisory/Consultancy, Research grant/Funding (self): Janssen; Non-remunerated activity/ies, Principal Investigator Keynote 189;MISP pembrolizumab in low expressors PD-L1(A.R. Filippi: Advisory/Consultancy, Scientific consultancy; advisory board: AstraZeneca; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: MSD. D. Christoph: Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: AstraZeneca; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Boehringer Ingelheim; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Bristol-Myers Squibb; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Chugai; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Merck, Sharp & Dohme; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Novartis; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Pfizer; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Roche; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Takeda; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Bayer. A. Agbarya: Non-remunerated activity/ies, Non-financial support: AstraZeneca. M. Van den Heuvel: Research grant/Funding (self), Research projects, not related to Pacific R: AstraZeneca. C. Chouaid: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: GSK; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Sanofi Aventis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Received fees for attending scientific meetings; speaking; organizing research; consulting within past five years: Amgen. E. Pichon: Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Bristol Myers Squibb; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support: Takeda; Non-remunerated activity/ies, Non-financial support: Merck Serono; Non-remunerated activity/ies, Non-financial support: AstraZeneca; Honoraria (self), Personal fees: Roche. S. Siva: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Speaker fees to institution and travel: AstraZeneca; Research grant/Funding (self), Research grant, un-related: Varian Industries. B. Solomon: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Roche/Genentech; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: Merck. L. Decoster: Research grant/Funding (self), Data monitoring: AstraZeneca; Travel/Accommodation/Expenses, Travel grant: Roche Belgium; Research grant/Funding (self): Boehringer Ingelheim; Travel/Accommodation/Expenses, Travel grant: MSD Belgium. W. Sawyer: Full/Part-time employment: AstraZeneca. M. Licour: Shareholder/Stockholder/Stock options, Full/Part-time employment, Employment/stock options: AstraZeneca. N. Girard: Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support outside the submitted work: AstraZeneca; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support outside the submitted work: BMS; Honoraria (self), Non-remunerated activity/ies, Personal fees and non-financial support outside the submitted work: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings